Therapeutic Solutions International, Inc.

OTCPK:TSOI Stock Report

Market Cap: US$2.5m

Therapeutic Solutions International Past Earnings Performance

Past criteria checks 0/6

Therapeutic Solutions International's earnings have been declining at an average annual rate of -15.1%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 37.4% per year.

Key information

-15.1%

Earnings growth rate

8.2%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate37.4%
Return on equity-173.5%
Net Margin-2,191.9%
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Therapeutic Solutions International makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:TSOI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-211
30 Sep 230-321
30 Jun 230-321
31 Mar 230-421
31 Dec 220-421
30 Sep 220-422
30 Jun 220-422
31 Mar 220-321
31 Dec 210-321
30 Sep 210-220
30 Jun 210-210
31 Mar 210-211
31 Dec 200-211
30 Sep 200-210
30 Jun 200-210
31 Mar 200-110
31 Dec 190-210
30 Sep 190-210
30 Jun 190-210
31 Mar 190-210
31 Dec 180-210
30 Sep 180-110
30 Jun 180-110
31 Mar 180-110
31 Dec 170-110
30 Sep 170-110
30 Jun 170-110
31 Mar 170-110
31 Dec 160-110
30 Sep 160-110
30 Jun 160-110
31 Mar 160-110
31 Dec 150-110
30 Sep 150-100
30 Jun 150000
31 Mar 150000
31 Dec 140-100
30 Sep 140000
30 Jun 140-110
31 Mar 140-110
31 Dec 130-110
30 Sep 13-1-210
30 Jun 13-1-220

Quality Earnings: TSOI is currently unprofitable.

Growing Profit Margin: TSOI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TSOI is unprofitable, and losses have increased over the past 5 years at a rate of 15.1% per year.

Accelerating Growth: Unable to compare TSOI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TSOI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).


Return on Equity

High ROE: TSOI has a negative Return on Equity (-173.55%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.